Table 3. Incidences of LOI of IGF2 in previous and present series of hepatoblastoma and Wilms' tumours.
| References | Total numbera | LOI of IGF2 | ROI of IGF2 | % |
|---|---|---|---|---|
| Hepatoblastoma | ||||
| Davies (1993) | 3 | 0 | 3 | 0 |
| Montagna et al (1994) | 5 | 1 | 4 | 20.0 |
| Rainier et al (1995) | 5 | 1 | 4 | 20.0 |
| Li et al (1995) | 3 | 1 | 2 | 33.3 |
| Fukuzawa et al (1999) | 4 | 1 | 3 | 25.0 |
| Ross et al (2000) | 13 | 3 | 10 | 23.1 |
| Hartmann et al (2000) | 5 | 3 | 2 | 60.0 |
| Total number | 38 | 10 | 28 | 26.3 |
| Present study | 42 | 9 | 33 | 21.4 |
| Wilms' tumour | ||||
| Ravenel et al (2001) | 36 | 15 | 21 | 41.7 |
| Yuan et al (2005) | 29 | 22 | 7 | 75.9 |
a
Tumours with LOH of IGF2 were excluded.